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Abstract
Background During the last decade, neoadjuvant
chemotherapy (NACT) of early breast cancer (EBC)
evolved from a therapy intended to enable operability to a
standard treatment option aiming for increasing cure rates
equivalent to adjuvant chemotherapy (ACT). In parallel,
improvements in the quality control of breast cancer care
have been established in specialized breast care units.
Patients and methods This study analyzed chemotherapy
usage in patients with EBC treated at the Heidelberg
University Breast Unit between January 2003 and
December 2014.
Results Overall, 5703 patients were included in the anal-
ysis of whom 2222 (39 %) received chemotherapy, 817
(37 %) as NACT, and 1405 (63 %) as ACT. The
chemotherapy usage declined from 48 % in 2003 to 34 %
in 2014 of the cohort. Further, the proportion of NACT
raised from 42 to 65 % irrespective of tumor subtype. In
addition, frequency of pathologic complete response (pCR)
defined as no tumor residues in breast and axilla (ypT0
ypN0) at surgery following NACT increased from 12 % in
2003 to 35 % in 2014. The greatest effect was observed in
HER2? breast cancer with an increase in patients achiev-
ing pCR from 24 to 68 %.
Conclusions The results mirror the refined indication for
chemotherapy in EBC and its preferred usage as NACT in
Germany. The increase in pCR rate over time suggests
improvement in outcome accomplished by a multidisci-
plinary decision-making process and stringent measures for
quality control.
Keywords Early breast cancer  Pathologic complete
response  Neoadjuvant chemotherapy  Adjuvant
chemotherapy  Certified breast cancer unit
Introduction
The insight of early breast cancer (EBC) as a systemic
disease was one of the fundamental breakthroughs in breast
cancer research and constitutes the basis for our therapy
decision making today. As a consequence, adjuvant sys-
temic therapy has become a backbone of EBC treatment. In
particular, the evolution of chemotherapy has contributed
substantially to the improved outcome of EBC patients
today [1]. That includes not only the introduction of
innovative cytotoxic drugs such as anthracyclines and
taxanes but also the development of novel treatment
approaches, i.e., dose-dense regimens and preoperative or
neoadjuvant therapy.
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Neoadjuvant chemotherapy (NACT) started as a treat-
ment option to enable or improve operability of inflam-
matory, locally advanced or large breast cancer tumors.
After equivalence in survival was confirmed, both adjuvant
chemotherapy (ACT) and NACT became the standard
treatment options for operable disease [2, 3]. NACT,
however, offers a number of unique benefits over ACT. It
improves the rate of breast-conserving surgery [2], allows
an in vivo testing for drug sensitivity, and provides
important prognostic information. The achievement of a
pathologic complete response (pCR) defined as no invasive
tumor residue in the breast and axilla following NACT is
associated with improved disease-free and overall survival
with the strongest correlation in aggressive breast cancer
subtypes [4, 5]. At the patient level, this has been con-
firmed recently by a large meta-analysis [6]. Furthermore,
post-neoadjuvant treatment may be differentiated depend-
ing on whether a patient achieves pCR after NACT or not.
This is currently investigated in several trials.
A breast cancer patient’s prognosis also depends on the
quality of treatment. To ensure patients are provided with a
standard-of-care treatment, the German Cancer Society
(DKG) and the German Society for Breast Diseases (DGS)
introduced a certification system in 2003. It builds on the
sustainable implementation of clinical guidelines in
everyday clinical care, the establishment of multidisci-
plinary teams, and a quality assurance system [7]. The
Heidelberg University Breast Care Unit (BCU) was fully
certified by the certification board of DKG and DGS in
2003.
We analyzed chemotherapy usage in routine clinical
care of a prospective cohort of 5703 patients with primary,
non-metastatic breast cancer treated at a specialized BCU
between January 2003 and December 2014.
Patient and methods
Patient selection
Data on medical history, demographic characteristics,
diagnostics, therapy, and follow-up of all patients referred
to the Heidelberg BCU for diagnosis and treatment of
primary breast cancer have been prospectively documented
since January 1, 2003 in our database. Patients were
managed under certified conditions verified continuously
by a re-certification process.
Our prospective database comprised 6639 patients with
primary breast cancer diagnosed and treated at Heidelberg
BCU between January 1, 2003 and December 31, 2014.
Nine hundred and thirty-six patients were excluded from
the analysis due to male sex (n = 45), no primary diag-
nosis (n = 23), M1 status at time of diagnosis (n = 364),
no surgery, or no histopathological report (n = 504). The
selection process is outlined as a Consort diagram in Fig. 1.
Patients had provided written informed consent on the use
of their demographic and treatment data.
Definitions of tumor histology and stages
Tumor histology was defined according to the World
Health Organization criteria [8]; grading was performed
and grouped into stages according to the most recent TNM
classification [9].
The expression of estrogen receptor (ER), progesterone
receptor (PgR), human epidermal growth factor receptor 2
(HER2), and Ki-67 was assessed using formalin-fixed
paraffin-embedded tumor tissue according to international
standards. Positivity for ER and PgR was defined as an
immunoreactive score (IRS) of Remmele and Stegner
of C1 out of 12 or as a total score (TS) of Allred of C1 out
of 8. Moreover, any positive staining (i.e., C1 %) was
defined as positive in accordance with the recent American
Society of Clinical Oncology (ASCO)/College of Ameri-
can Pathologists (CAP) guideline recommendations [10].
HER2 status was defined as positive in case of a semi-
quantitative HercepTest score of 3? by immunohisto-
chemistry (IHC) or in case of a positive FISH/CISH assay
as per ASCO/CAP guideline recommendations [11].
Based on ER, PgR, and HER2-status by IHC ± FISH/
CISH, three breast cancer subtypes were defined: 1) neg-
ative ER, PgR, and HER2 status corresponding to triple
negative (TN); 2) positive HER2 status to HER2-positive
(HER2?) irrespective of ER and PgR status; and 3) hor-
mone receptor (HR)-positive status defined as a positive
ER or a positive PgR status along with a negative HER2
status (HR? HER2-). For patients with NACT,
immunohistochemical information was based on the pre-
treatment biopsy, for patients with ACT on the final post-
surgery pathological sample.
Statistical analysis
Data were analyzed descriptively using SPSS software
version 22 (IBM, Armonk, USA). Annual and biannual
percentages of chemotherapy use were calculated and
presented as a longitudinal time trend analysis for the
period from 2003 to 2014.
Results
Patient and tumor characteristics
The final cohort comprised 5703 patients of which 2222
patients received chemotherapy, 1405 (63 %) as ACT, and
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817 (37 %) as NACT (Fig. 1). Demographic and tumor
characteristics are presented separately for patients with
ACT and NACT (Table 1). In the ACT cohort, the median
age of patients was 54 years, more than half of the women
were postmenopausal (54 %), and had a tumor grading of
G3 in 41 % of the cases. Almost half of the patients had a
tumor B2 cm (48 %) and were node-negative (48 %).
Patients in the NACT cohort tended to be younger
(median age 49 vs. 54 years), had a higher proportion of
G3 tumors (53 vs. 41 %), and had more often tumors with a
Ki-67[14 % (78 vs. 65 %) than patients who received
ACT. As expected, the tumor size distribution following
NACT shows a shift to smaller tumors with a relevant
percentage of ypT0 stage (29 %) and lower proportions of
(y)pT1 and (y)pT2 tumors (38 vs. 47 % and 19 vs. 41 %,
respectively). In the NACT cohort, 58 % of patients had a
HR? HER2-, 16 % a HER2? , and 26 % a TN subtype
as compared to the ACT cohort with 69 % HR? HER2-,
14 % HER2?, and 17 % TN.
Chemotherapy usage
Overall, the annual number of patients diagnosed and
treated at our center increased over time, while
chemotherapy usage declined. In 2003, 48 % of patients
with EBC received chemotherapy compared to only 34 %
in 2014 (Fig. 2). This is a steady decrease in the usage of
chemotherapy from 2003 to 2014 of 14 %. In parallel,
there was a shift in the relative proportions from ACT
toward NACT. Figure 3 demonstrates a peak of 84 % for
the use of ACT in 2008. The relative proportion of NACT
increased continuously thereafter with a steep rise from
2011 to 2012. In 2014, the use of ACT dropped to 35 %,
whereas the use of NACT amounted to 65 % (Fig. 3). The
shift from ACT to NACT was seen irrespective of breast
cancer subtype (Fig. 4). The relative proportion of NACT
by breast cancer subtype in 2014 was highest in TN tumors
with 75 %, following HER2? tumors with 70 % and in
HR? HER2- tumors with 58 %.
T-stage distribution
The pT-stage distribution of patients receiving ACT
remained stable over the whole period under review (see
Supplementary Fig. S1a). However, the relative proportion
of ypT-stages in the NACT cohort changed considerably
over time. Overall, there was an evolution to more favor-
able stages after admission of NACT. The percentage of
patients with a postoperative ypT0 stage rose continuously
from 16 % in 2003/2004 to 37 % in 2013/2014 and the rate
of ypTis increased from 3 to 6 %, respectively. At the same
time, the relative proportion of ypT1 stages decreased from
Fig. 1 CONSORT diagram
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Table 1 Patient and tumor
characteristics of all female
cases with primary, non-
metastatic breast cancer who
were diagnosed and treated at
Heidelberg University Breast
Care Unit between 01.01.2003
and 31.12.2014 and underwent






Number % Number %
Age at diagnosis in years
Median 54 years 49 years
\51 576 41 469 57
51–65 566 40 267 33
[65 263 19 81 20
Menopausal status
Pre 593 43 425 53
Peri 45 3 53 7
Post 740 54 319 40
Missing 27 – 20 –
Affected breast
Left 704 50 420 51
Right 701 50 397 49
Main tumor histology
Invasive carcinoma no specific type 1185 84 662 81
Invasive lobular carcinoma 180 13 122 15
Other (e.g., invasive medullar/mixed) 40 3 33 4
Post-surgical T-stage
T0 0 0 223 29
T1 659 47 310 38
T2 569 41 153 19
T3 118 8 59 7
T4 22 2 22 3
Tis 0 0 44 5
Tx 37 3 7 1
Post-surgical N stage
N0 674 48 540 66
N1 374 27 165 20
N2 179 13 67 8
N3 135 10 32 4
Nx 43 3 13 2
Grading
Grade 1 66 5 15 2
Grade 2 751 55 307 45
Grade 3 559 41 361 53
Missing 29 – 134 –
Estrogen receptor
Positive 1040 74 524 64
Negative 360 26 293 36
Missing 5 – 0 –
Progesterone receptor
Positive 958 68 470 58
Negative 440 31 347 43
Missing 7 – 0 –
HER2 receptor
Positive 193 14 133 16
Negative 1206 86 684 84
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48 to 37 % and that of ypT3/4 stages from 16 to 5 %,
respectively (see Supplementary Fig. S1b).
Response to neoadjuvant chemotherapy
The shift to more favorable postoperative ypT-stages in the
NACT cohort corresponded with an increase in the pro-
portion of patients achieving a pCR over time (Fig. 5).
PCR rate according to the most stringent definition (ypT0
ypN0) was 12 % in 2003 rising to 35 % in 2014. The effect
was most prominent in tumors of the HER2? subtype with
pCR rising from 24 % in 2003/2004 to 68 % in 2013/2014.
An increase in pCR was also seen in HR? HER2- tumors
with a rise from 4 to 23 %, respectively. However, there
was no clear trend regarding pCR rates in TN disease
(Fig. 6).
Discussion
Our results reflect the fundamental developments in the
usage of chemotherapy in early breast cancer patients.
Since the advent of molecular classification systems, it has
become evident that systemic therapy of EBC needs to be
tailored according to individual risk factors and intrinsic
subtype. Modern microarray-based gene expression pro-
files are the best way to visualize the heterogeneity of
breast cancer with a more widely use in clinical routine in
recent years. Patients that can be spared chemotherapy
have been identified [2, 12]. Thus, it is reassuring that this
leads to a substantial decline of overall chemotherapy use
in EBC over time.
Another finding of our analysis was the considerable
shift from ACT to NACT including a major increase of
Fig. 2 Overall proportion of patients receiving chemotherapy among primary, non-metastatic breast cancer patients at Heidelberg Breast Care







Number % Number %
Missing 6 – 0 –
Ki-67
B14 % 421 36 139 22
[14 % 764 65 504 78
Missing 220 – 174 –
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Fig. 3 Relative proportion of adjuvant and neoadjuvant chemotherapy at Heidelberg Breast Care Unit from 2003 to 2014
Fig. 4 Relative proportion of NACT by breast cancer subtype (n = 2215, 7 missing) at Heidelberg Breast Care Unit from 2003 to 2014
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NACT from 2011 to 2012. To some extent, this may reflect
the altered understanding and recognition of NACT. In
2009, the consensus conference of St. Gallen still stated that
neoadjuvant systemic therapy was considered justified pri-
marily to enhance the possibility of breast-conserving sur-
gery [13]. However, in 2011, the prognostic value of NACT
was finally acknowledged by the St. Gallen consensus
conference [12]. NACT use in HER2? tumors constitutes a
significant proportion of the overall NACT use. Thus, the
course of the curve may also have been influenced by the
availability of trastuzumab outside clinical trials. The peak
use of ACT and the minimum use of NACT were in 2007. In
2006, trastuzumab was first approved for adjuvant use in
HER2? EBC, and the application of trastuzumab in
HER2? disease as part of NACT was still deemed inves-
tigational [14]. Finally, however at the end of 2011, trastu-
zumab was also approved in combination with NACT.
While a survey in 2014 of a representative sample of
25 % of all German breast centers found a NACT rate of
15 % in all and of 26 % in highly specialized centers [15],
65 % of EBC patients at our center received NACT in the
same period. This high rate is probably grounded on our
longstanding engagement as an institution and as individ-
ual researchers in studying and developing NACT.
In addition, there was a clear improvement in the
response to NACT. Our results compare favorably with the
results of the major clinical trials. The pCR rate in all three
subtypes documented in 2014 tended to be even higher
than what is reported in the literature. While we reached
pCR rates (ypT0 ypN0) of 46 % in TN, 68 % in
HER2? and 23 % in HR? HER2- subtypes, the
CTNeoBC pooled analysis reported rates of 34 % for TN,
31 % and 50 % for HER2? HR? and HER2? HR-
treated with trastuzumab, and 16 % for HR? HER2- G3
based on a less conservative pCR definition (ypT0/is ypN0)
[6]. The highest pCR (yp T0 ypN0) rates for HER2? and
for HER2? HR– tumors reported so far were 52 and 84 %
with chemotherapy plus trastuzumab and pertuzumab,
respectively [16].
It is unlikely that this results from us using a different
chemotherapy regimen or a major change in our choice of
chemotherapy. In 2003, NACT was already anthracycline
and taxane-based [17], and it still is in 2014 [2, 3]. One can
argue that in HER2? disease, the adoption of trastuzumab
had an impact. Treatment of HER2? patients with
chemotherapy plus a dual HER2 blockade with trastuzu-
mab and pertuzumab within clinical trials may have con-
tributed to the further improvement from 2011/2012 to
Fig. 5 pCR according to different definitions of pCR at Heidelberg Breast Care Unit from 2003 to 2014
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2013/2014. But the improvement in outcomes probably
also reflects our learning curve in selecting the appropriate
patients with aggressive tumor biology for NACT. We
believe they are also the result of the rigorous quality
management and control of Heidelberg as a certified BCU.
Moreover, it was shown that participation in clinical trials
is associated with better outcomes [18].
Finally, achieving pCR is associated with a better prog-
nosis for the individual patient, in particular, for those with
aggressive breast cancer subtypes like HR? G3, HER2?, -
and TN breast cancer [4–6]. Thus, it is reassuring that we
improved in providing this clinical benefit to EBC patients.
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